SUBUTEX (buprenorphine) sublingual tablet is an uncoated oval white flat beveled-edged tablet, debossed with an alphanumeric word identifying the product and strength on one side. It contains buprenorphine HCl, a partial agonist at the mu-opioid receptor, and is available in two dosage strengths, 2 mg buprenorphine and 8 mg buprenorphine (as the free base, equivalent to 2.16 mg buprenorphine hydrochloride USP and 8.64 mg buprenorphine hydrochloride USP). Each tablet also contains lactose, mannitol, cornstarch, povidone K30, citric acid, sodium citrate, and magnesium stearate.
Chemically, buprenorphine HCl is (2S)-2-[17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy6α,14-ethano-14α-morphinan-7α-yl]-3,3-dimethylbutan-2-ol hydrochloride. It has Buprenorphine HCl has the molecular formula C29 H41 NO4 • HCl and the molecular weight is 504.10. It is a white or off-white crystalline powder, sparingly soluble in water, freely soluble in methanol, soluble in alcohol, and also practically insoluble in cyclohexane.
SUBUTEX is indicated for the treatment of opioid dependence and is preferred for induction. SUBUTEX should be used as part of a complete treatment plan to include counseling and psychosocial support.
DOSAGE AND ADMINISTRATION OF SUBUTEX
Drug Addiction Treatment Act
Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to healthcare providers who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and also have been assigned a unique identification number that must be included on every prescription.
Dosage Forms And Strengths
SUBUTEX sublingual tablet is supplied as an uncoated oval white tablet in two dosage strengths:
buprenorphine 2 mg,
Storage And Handling
SUBUTEX sublingual tablet is an uncoated oval white flat beveled-edged tablet, debossed with an alphanumeric word identifying the product and also strength on one side (“B2” and “B8” on 2 mg and 8 mg tablets respectively), supplied in desiccated high-density polyethylene (HDPE) bottle:
NDC 12496-1310-2 (buprenorphine 8 mg/sublingual tablet; content expressed in terms of the free base, equivalent to 8.64 mg buprenorphine hydrochloride USP) -30 tablets per bottle
Store at 25°C (77°F), excursions permitted to 15°-30°C (59°-86°F).
Advise patients to store buprenorphine-containing medications safely and also out of sight and reach of children and to destroy any unused medication appropriately
SUBOXONE is preferred for maintenance treatment.
Where SUBUTEX is used in maintenance in patients who cannot tolerate the presence of naloxone, the dosage of SUBUTEX should be progressively adjusted in increments/decrements of 2 mg or 4 mg buprenorphine to a level that holds the patient in treatment and also suppresses opioid withdrawal signs and symptoms.
After treatment induction and stabilization, the maintenance dose of SUBUTEX is generally in the range of 4 mg to 24 mg buprenorphine per day depending on the individual patient. The recommended target dosage of SUBUTEX is 16 mg as a single daily dose. Dosages higher than 24 mg have not been demonstrated to provide any clinical advantage.
When determining the prescription quantity for unsupervised administration, consider the patient’s level of stability, the security of his or her home situation, and other factors likely to affect the ability to manage supplies of take-home medication.
There is no maximum recommended duration of maintenance treatment. Patients may require treatment indefinitely and should continue for as long as patients are benefiting and the use of SUBUTEX contributes to the intended treatment goals.
Method Of Administration
SUBUTEX must be administered whole. Do not cut, chew, or swallow SUBUTEX. Advise patients not to eat or drink anything until the tablet is completely dissolved. SUBUTEX should be placed under the tongue until it is dissolved.
For doses requiring the use of more than two tablets, patients are advised to either place all the tablets at once or alternatively (if they cannot fit in more than two tablets comfortably), place two tablets at a time under the tongue. Either way, the patients should continue to hold the tablets under the tongue until they dissolve; swallowing the tablets reduces the bioavailability of the drug. To ensure consistency in bioavailability, patients should follow the same manner of dosing with continued use of the product.
Proper administration techniques should be demonstrated to the patient.
Buy Subutex 2mg and also other Medicine Online from POWERALL PHARMACY.
Order Suboxone 2mg online – No Prescription Needed.
Buy Subutex (Buprenorphine) 2mg Online – Overnight Shipping,
Order Buprenorphine online US, UK, CANADA. Buy Buprenorphine without prescription.
SUBUTEX:(buprenorphine) Sublingual Tablets